Iterum Therapeutics plc (ITRM)

Market Cap	51.53M
Revenue (ttm)	n/a
Net Income (ttm)	-24.77M
Shares Out	34.58M
EPS (ttm)	-1.26
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	313,614
Open	1.500
Previous Close	1.490
Day's Range	1.470 - 1.540
52-Week Range	0.808 - 3.020
Beta	2.27
Analysts	Strong Buy
Price Target	5.00 (+235.57%)
Earnings Date	Feb 7, 2025

About ITRM

Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with limited or no alternative oral antibacterial treatment options. It is also developing sulopenem, a novel anti-infective compound with oral and intravenous...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 25, 2018
• Employees: 9
• Stock Exchange: NASDAQ
• Ticker Symbol: ITRM
• Website: https://www.iterumtx.com

Analyst Forecast

According to one analyst, the rating for ITRM stock is "Strong Buy" and the 12-month stock price forecast is $5.0.

Price Target

$5.0

(235.57% upside)

Analyst Consensus: Strong Buy